Abstract Number: 0612 • ACR Convergence 2025
Is Antimalarial Use Associated with a Reduced Risk of Lupus Nephritis in Patients with SLE? Results from an Inception Cohort-Based Study
Background/Purpose: Antimalarials, particularly hydroxychloroquine, are a cornerstone of systemic lupus erythematosus (SLE) management, with well-established benefits including reduced disease activity, prevention of flares, and mitigation…Abstract Number: 0596 • ACR Convergence 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the…Abstract Number: 0802 • ACR Convergence 2025
Remission from cutaneous manifestations of lupus with enpatoran, a first-in-class oral small molecule toll-like receptor 7/8 inhibitor: pooled post-hoc exploratory analysis from a randomized placebo-controlled Phase II study
Background/Purpose: Cutaneous manifestations of lupus are highly prevalent and have a significant impact on patients’ physical and mental health and wellbeing; however, no targeted therapy…Abstract Number: 0218 • ACR Convergence 2025
Creating an EHR Lupus Outreach Workbench to Address Care Gaps
Background/Purpose: Lupus affects up to 1.5 million people in the US with significant health disparities in care and outcomes that call for care delivery innovation.…Abstract Number: 0023 • ACR Convergence 2025
Longitudinal Proteomic Effects of Hydroxychloroquine in Individuals at Risk of Lupus: Differential Signatures in Progressors and Non-Progressors
Background/Purpose: Hydroxychloroquine (HCQ) is routinely prescribed for treatment of systemic lupus erythematosus (SLE) due to its efficacy at decreasing disease activity/SLE flares and strong benefit:risk…Abstract Number: 2696 • ACR Convergence 2025
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Background/Purpose: Current evidence suggests that B cell depletion through CD19-directed chimeric antigen receptor T cell (CAR-T) therapies may offer promise in improving outcomes in severe…Abstract Number: 2602 • ACR Convergence 2025
Cellular and molecular fine mapping in single-cell data pinpoints new immunopathology of systemic lupus erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with unknown etiology. While we previously identified key gene signatures of SLE using bulk RNA-seq…Abstract Number: 2468 • ACR Convergence 2025
RESET-SLE: Clinical Trial Evaluating Rese-cel (Resecabtagene Autoleucel), a Fully Human, Autologous 4-1BB CD19-CAR T Cell Therapy in Non-Renal SLE and Lupus Nephritis
Background/Purpose: Current goals of treatment for systemic lupus erythematosus (SLE) are to achieve low disease state/remission, prevent flares, minimize organ damage, and decrease long-term morbidity…Abstract Number: 2450 • ACR Convergence 2025
Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)
Background/Purpose: Anifrolumab is a biologic recently approved for systemic lupus erythematosus (SLE), with efficacy shown in trials, but data from real-world practice remain limited. The…Abstract Number: 2433 • ACR Convergence 2025
The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
Background/Purpose: Timely SLE diagnosis and treatment are critical to preventing irreversible organ damage and preserving quality of life. However, conventional biomarkers often underperform in patients…Abstract Number: 2414 • ACR Convergence 2025
Autoantibody Clusters and SIGLEC1 are Predictive of Systemic Lupus Erythematosus Development
Background/Purpose: Up to a third of those with suspected SLE progress to definite SLE; however, reliable predictive markers for disease progression remain unknown. Previously, we…Abstract Number: 2396 • ACR Convergence 2025
A Machine Learning Algorithm Based on a 15-Autoantibody Profile by a Novel Fully Automated Multiplexed Microarray Immunoassay for the Diagnosis of Autoimmune Connective Tissue Diseases
Background/Purpose: Detection of relevant autoantibodies is key in the identification of autoimmune connective tissue diseases (CTD). The evaluation of multiple autoantibodies for extended serological profiling…Abstract Number: 2380 • ACR Convergence 2025
Factors Influencing Time to Diagnosis in Systemic Lupus Erythematosus: A Real-World Retrospective Analysis
Background/Purpose: Individuals with Systemic lupus erythematosus (SLE) face diagnostic delays that can lead to increased disease activity and organ damage. Using a large electronic health…Abstract Number: 2206 • ACR Convergence 2025
Adolescents with Systemic Lupus Erythematosus at Highest Risk of Adverse Pregnancy Outcomes
Background/Purpose: Few studies exist that examine pregnancy outcomes in adolescents with SLE. To our knowledge, there have been no studies comparing SLE adolescent pregnancies to…Abstract Number: 1925 • ACR Convergence 2025
Associations between Representation and Quality in Clinical Trials for Systemic Lupus Erythematosus
Background/Purpose: Drug development in SLE is informed by US Food and Drug Administration recommendations for study design, enrollment, and efficacy endpoints. However, persistent challenges to…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 181
- Next Page »